Benzinga · Oct 29, 2026
Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44
Canaccord Genuity analyst Whitney Ijem maintains Wave Life Sciences (NASDAQ:WVE) with a Buy and raises the price target from $42 to $44.
WV
NASDAQ · WVE
Wave Life Sciences Ltd.
Healthcare · Biotechnology
$3.58
Up+$0.04 (+1.12%)
Updated Nov 4, 2026, 9:30 PM
SID Score
3.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.75B
- P/E ratio
- -23.03
- Dividend yield
- 0.00%
- 52-week range
- $3.04 – $14.32
- Volume
- 3.84M
- Avg. volume
- 5.46M
Price performance · WVE
WVE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
WVE closed at $3.58 after 21 trading sessions, up 1.70% for the selected period.
- Last close
- $3.58
- Period change
- +1.70%
- Period low
- $3.09
- Period high
- $3.64
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.55 | $3.665 | $3.54 | $3.58 | 3.84M |
| Nov 2, 2026 | $3.64 | $3.69 | $3.43 | $3.52 | 1.94M |
| Oct 30, 2026 | $3.62 | $3.6999 | $3.4301 | $3.59 | 3.33M |
| Oct 29, 2026 | $3.75 | $3.86 | $3.60 | $3.63 | 3.59M |
| Oct 28, 2026 | $3.44 | $3.77 | $3.36 | $3.64 | 4.26M |
| Oct 27, 2026 | $3.55 | $3.55 | $3.235 | $3.45 | 4.2M |
| Oct 26, 2026 | $3.17 | $3.235 | $3.13 | $3.21 | 3.22M |
| Oct 23, 2026 | $3.33 | $3.34 | $3.12 | $3.18 | 2.66M |
| Oct 22, 2026 | $3.36 | $3.43 | $3.34 | $3.35 | 1.85M |
| Oct 21, 2026 | $3.42 | $3.48 | $3.35 | $3.37 | 2.17M |
| Oct 20, 2026 | $3.18 | $3.49 | $3.18 | $3.42 | 3.62M |
| Oct 19, 2026 | $3.15 | $3.19 | $3.08 | $3.17 | 1.87M |
| Oct 16, 2026 | $3.24 | $3.28 | $3.08 | $3.13 | 3.28M |
| Oct 15, 2026 | $3.13 | $3.23 | $3.08 | $3.19 | 3.35M |
| Oct 14, 2026 | $3.09 | $3.13 | $3.0399 | $3.09 | 2.83M |
| Oct 13, 2026 | $3.27 | $3.27 | $3.07 | $3.14 | 4.18M |
| Oct 12, 2026 | $3.46 | $3.46 | $3.27 | $3.28 | 2.26M |
| Oct 9, 2026 | $3.49 | $3.525 | $3.43 | $3.46 | 1.66M |
| Oct 8, 2026 | $3.48 | $3.51 | $3.365 | $3.47 | 2.66M |
| Oct 7, 2026 | $3.48 | $3.60 | $3.43 | $3.54 | 3.05M |
| Oct 6, 2026 | $3.78 | $3.815 | $3.4815 | $3.52 | 3.45M |
Latest WVE news
The latest Smart Investors Daily articles mentioning WVE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
WVE research
Overview
Company profile and research snapshot.
Company profile
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $29.22
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Canaccord Genuity | Buy | — |
| Oct 28, 2026 | Oppenheimer | Outperform | — |
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 15, 2026 | UBS | Buy | — |
| Oct 1, 2026 | Ladenburg Thalmann | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Wave Life Sciences (WVE) Stock Rallies As Q3 Results Ease Loss Fears
Wave Life Sciences just dropped its Q3 2026 print and the stock is up about 7% intraday. That bounce looks like a reaction to relief as much as results. Revenue landed at US$13.2 million and the company still booked a sizeable net loss of US$61.9 million, so this move is not about a clean profit story. The real driver is sentiment around whether that loss profile is becoming more manageable. Traders are treating today as a vote of confidence in Wave Life Sciences’ trajectory, even though the...
Benzinga · Oct 28, 2026
Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29
Oppenheimer analyst Cheng Li maintains Wave Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $32 to $29.
Yahoo · Oct 28, 2026
Wave Life Sciences Ltd. Q3 2026 Earnings Call Summary
Moby summary of Wave Life Sciences Ltd.'s Q3 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
